Healthcare
Live Price
Offline$11.46
+0.44% today
1Y Change
+21.91%
Window
Jun 25, 2025 โ Jun 22, 2026
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cipher Pharmaceuticals Inc. (CPHRF) is a Healthcare stock with a market cap of $340.00M and listed on OTC. The stock last traded around $11.46 and up 21.9% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +53.9%, EPS growth of +131.9%, a dividend yield of 0.0%. What stands out right now is revenue +53.9%, EPS +131.9%, free cash flow +54.9% with operating margin 33.0% and ROIC 12.7%. Valuation is more restrained than many high-expectation growth names at P/E 12.2 and price/sales 6.6. Stock Foundry combines CPHRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+53.9% vs +7.6% peer median
Operating Margin
Above sector median
+33.0% vs +19.4% peer median
P/E
Below sector median
12.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +53.9% and EPS at +131.9%, with operating margin around 33.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.6% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +10.0% | -2.4% | -8.2% |
2026 Mar 12, 2026 | +229.0% | +15.3% | +14.4% | +26.8% |
2025 Nov 6, 2025 | +43.5% | -8.7% | -10.2% | +0.6% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CPHRF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CPHRF Max Drawdown
-24.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CPHRF and SPY.
Company Overview
Cipher Pharmaceuticals Inc.
OTC
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing new formulations of existing medications, predominantly in the dermatology and hospital markets. The company's primary function is to enhance therapeutic outcomes by improving drug efficacy and patient compliance through proprietary delivery systems. Cipher Pharmaceuticals leverages its expertise in drug reformulation to bring innovative products to market that address unmet medical needs. Operating mainly in North America, the company works in collaboration with various commercial partners to ensure broad distribution and marketing of its pharmaceutical solutions. Notable features of Cipher's portfolio include treatments for skin conditions such as severe acne, plaque psoriasis, and onychomycosis. In the financial markets, Cipher Pharmaceuticals Inc. has carved a niche by focusing on specialized areas within the pharmaceutical industry, driving growth through strategic acquisitions and partnerships. Its role is significant in introducing niche pharmaceutical products that cater to specific patient populations, thereby contributing to the broader healthcare ecosystem by enhancing patient care and expanding therapeutic offerings.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.